Oragenics Inc. (OGEN)

0.47
0.00 0.13
AMEX : Health Technology
Prev Close 0.47
Open 0.47
Day Low/High 0.47 / 0.48
52 Wk Low/High 0.38 / 3.74
Volume 211.07K
Avg Volume 1.18M
Exchange AMEX
Shares Outstanding 46.12M
Market Cap 22.01M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oragenics, Inc. Provides Development Update Of AG013 For Oral Mucositis

Oragenics, Inc. Provides Development Update Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced development updates regarding the Company's lead compound for OM, AG013.

Newly Published Preclinical Data On Oragenics, Inc.'s Lantibiotic Compound Demonstrates Tolerability And Compartmentalization To The GI Tract

Newly Published Preclinical Data On Oragenics, Inc.'s Lantibiotic Compound Demonstrates Tolerability And Compartmentalization To The GI Tract

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced the publication of preclinical data of the company's lantibiotic compound...

Oragenics, Inc. To Present At Spring Investor Summit On April 1, 2019

Oragenics, Inc. To Present At Spring Investor Summit On April 1, 2019

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at Spring Investor Summit on April...

Oragenics, Inc. Enters Into Collaboration With Florida International University To Expand Its Pipeline Of Lantibiotics

Oragenics, Inc. Enters Into Collaboration With Florida International University To Expand Its Pipeline Of Lantibiotics

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced the initiation of a collaboration with Florida International University...

Oragenics Announces Closing Of $12.5 Million Underwritten Public Offering

Oragenics Announces Closing Of $12.5 Million Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the closing of its previously announced underwritten public offering of...

Oragenics Announces Pricing Of $12.5 Million Underwritten Public Offering

Oragenics Announces Pricing Of $12.5 Million Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the pricing of its previously announced underwritten public offering of...

Organics Announces Proposed Underwritten Public Offering

Organics Announces Proposed Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has commenced a proposed underwritten public offering of common stock of...

Oragenics, Inc. Announces Enrollment Of 60th Patient In Clinical Trial

Oragenics, Inc. Announces Enrollment Of 60th Patient In Clinical Trial

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the enrollment of the 60 th patient in its Phase 2 double blind, placebo...

Oragenics Inc. To Attend The Roth Capital 31st Annual Growth Conference March 17 - 19, 2019

Oragenics Inc. To Attend The Roth Capital 31st Annual Growth Conference March 17 - 19, 2019

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced that Alan Joslyn, Ph.

Oragenics, Inc. Receives Further Validation For Lantibiotic Compound OG716

Oragenics, Inc. Receives Further Validation For Lantibiotic Compound OG716

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces the publication of a preclinical study using the lead compound from its...

Oragenics Inc. To Present At NobleCon15 On January 28, 2019

Oragenics Inc. To Present At NobleCon15 On January 28, 2019

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), announced today that Alan Joslyn, Ph.

Oragenics, Inc. Announces Publication Detailing The Development Of Blueprints For Designing A New Class Of Anti-Infectives

Oragenics, Inc. Announces Publication Detailing The Development Of Blueprints For Designing A New Class Of Anti-Infectives

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper titled "Blueprints for the rational design of therapeutic mutacin 1140 variants," in Chemical Biology & Drug...

Oragenics, Inc. Receives Clearance To Enroll Patients In Germany And The United Kingdom Into Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. Receives Clearance To Enroll Patients In Germany And The United Kingdom Into Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced it has received clearance to enroll patients residing in Germany from the...

Oragenics, Inc. Announces 3Q 2018 Financial Results And Provides Corporate Update

Oragenics, Inc. Announces 3Q 2018 Financial Results And Provides Corporate Update

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results for the quarter ended September 30, 2018.

Oragenics, Inc. Receives Clearance To Enroll Patients In Belgium Into Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. Receives Clearance To Enroll Patients In Belgium Into Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced it has received clearance to enroll patients residing in Belgium from the...

Oragenics, Inc. To Present At Upcoming Conferences In October

Oragenics, Inc. To Present At Upcoming Conferences In October

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at The MicroCap Conference on...

Oragenics, Inc. To Present Data From Its Lantibiotics Program At The Boulder Peptide Symposium Monday, September 24, 2018

Oragenics, Inc. To Present Data From Its Lantibiotics Program At The Boulder Peptide Symposium Monday, September 24, 2018

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced that Dr.

Oragenics, Inc. Resumes Phase 2 Clinical Trial Of AG013 In Oral Mucositis Following Positive Routine Safety Review

Oragenics, Inc. Resumes Phase 2 Clinical Trial Of AG013 In Oral Mucositis Following Positive Routine Safety Review

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic...

Oragenics, Inc. Announces Closing Of $13.8 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option

Oragenics, Inc. Announces Closing Of $13.8 Million Underwritten Public Offering And Full Exercise Of Over-Allotment Option

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced the closing of an underwritten public offering of units for gross proceeds of approximately $13.

Oragenics, Inc. Announces Pricing Of $12 Million Underwritten Public Offering

Oragenics, Inc. Announces Pricing Of $12 Million Underwritten Public Offering

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and...

Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery Of OG716 For C. Difficile Infections

Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery Of OG716 For C. Difficile Infections

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper entitled " OG716: designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile...

Oragenics, Inc. And Texas A&M University System Granted U.S. Patent For Lantibiotic MU1140

Oragenics, Inc. And Texas A&M University System Granted U.S. Patent For Lantibiotic MU1140

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.

Oragenics, Inc. Announces Pricing Of $1.8 Million Registered Direct Offering

Oragenics, Inc. Announces Pricing Of $1.8 Million Registered Direct Offering

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced that it has entered into a securities purchase agreement with certain new institutional investors...

Oragenics Completes Enrollment For The Interim Analysis Cohort In Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics Completes Enrollment For The Interim Analysis Cohort In Its Phase 2 Clinical Trial Of AG013 For Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has completed enrollment of the interim...

Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy Of Mutacin 1140 Lantibiotic Variants Against Clostridium Difficile

Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy Of Mutacin 1140 Lantibiotic Variants Against Clostridium Difficile

Oragenics, Inc. (NYSE American: OGEN) (the "Company"), a clinical stage biotechnology company, today announced the publication of a research paper entitled "Mutacin 1140 Lantibiotic Variants Are Efficacious Against...

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. (NYSE American: OGEN) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on February 16, 2018 with the Securities and...

Oragenics, Inc. Announces Reverse Stock Split

Oragenics, Inc. Announces Reverse Stock Split

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE American: OGEN) (the "Company") today announced a reverse split of its common stock, $0.